Hormone therapy and libido in women: estrogen, testosterone and the evidence
Hormone therapy can help a woman's sex life, but the type of hormone matters. Vaginal estrogen and prasterone (vaginal DHEA) reliably treat dryness and painful sex after menopause, while systemic estrogen gives only a small to moderate improvement in sexual function, mostly in women with menopausal symptoms. Testosterone is the one hormone with evidence for low desire itself, and only for hypoactive sexual desire disorder (HSDD) in postmenopausal women.
Low desire caused by stress, relationship strain, depression or certain medications usually needs a different fix, which is why the right workup matters more than any single prescription. Longevity is not accidental, it is intentional, and that includes your sex life. Here is what each option actually does, according to the guidelines and the best available reviews.
Vaginal estrogen and DHEA: the fix for dryness and painful sex
For many women, the "libido problem" after menopause is really a pain problem. Falling estrogen thins and dries the vaginal and vulvar tissue, reduces natural lubrication and can cause burning, urinary urgency and pain during sex. Doctors call this genitourinary syndrome of menopause (GSM). When sex hurts, your brain learns to avoid it, and desire drops as a result.
The Menopause Society's 2022 Hormone Therapy Position Statement recommends low dose vaginal estrogen for GSM symptoms that do not improve with over the counter lubricants and moisturizers. Because it is applied locally at a low dose, very little reaches the bloodstream. It comes as a cream, a small vaginal tablet or insert, or a ring.
Two other FDA-approved options treat painful sex caused by menopause:
- Prasterone (vaginal DHEA): a nightly vaginal insert that the vaginal cells convert into estrogens and androgens locally.
- Ospemifene: an oral pill that acts like estrogen on vaginal tissue, for women who prefer not to use a vaginal product.
What these treatments do not do is raise desire directly. They repair tissue. For a woman whose interest faded because sex became painful, though, that repair is often what brings interest back.
Systemic hormone therapy: a modest effect on desire
Systemic hormone therapy means estradiol taken as a pill, patch, gel or spray, plus a progestogen if you still have a uterus. Its main job is treating hot flashes, night sweats and the sleep disruption that comes with them.
A Cochrane review summarized in American Family Physician in 2024 looked at whether this kind of therapy improves sexual function. The findings were measured:
- Estrogen alone or combined with a progestogen was associated with a small to moderate improvement in sexual function in women with menopausal symptoms or in early postmenopause.
- In postmenopausal women in general, not selected for symptoms, there was little or no benefit.
- The certainty of the evidence was limited, so the size of any effect should be read with caution.
In practical terms: if your libido dropped at the same time hot flashes and broken sleep took over, treating those symptoms may help you feel like yourself again, and desire can follow. Systemic estrogen is not a libido drug on its own. Oral estrogen also raises sex hormone binding globulin, a protein that lowers the amount of free testosterone in circulation, which is one reason clinicians sometimes favor transdermal estradiol when sexual function is a concern.
| Option | Main target | Evidence for sexual concerns | FDA status for this use |
|---|---|---|---|
| Low dose vaginal estrogen | Dryness, pain with sex (GSM) | Strong for GSM symptoms | Approved for menopausal vaginal symptoms |
| Prasterone (vaginal DHEA) | Painful sex after menopause | Supported for pain with intercourse | Approved |
| Systemic estrogen (with progestogen if uterus) | Hot flashes, sleep; sexual function secondary | Small to moderate benefit in symptomatic women | Approved for menopausal symptoms, not for libido |
| Transdermal testosterone | Low desire with distress (postmenopausal HSDD) | Consensus-supported for this one diagnosis | No approved product for women in the US |
| Flibanserin, bremelanotide | Low desire (premenopausal HSDD) | Modest benefit | Approved for premenopausal women |
Testosterone for postmenopausal HSDD: what the Global Consensus says
Testosterone is the hormone most people associate with sex drive, and for women it has a real but narrow role. The clearest guidance comes from the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, written by an international expert panel and supported by major menopause and endocrine societies.
The key points:
- One evidence-based indication. Testosterone is supported for hypoactive sexual desire disorder in postmenopausal women. HSDD means persistently low desire that causes you distress and is not better explained by pain, relationship problems, depression, medications or another condition.
- A moderate benefit. In trials, women with HSDD reported improvements in desire, arousal, orgasm, pleasure and satisfying sexual events, along with less distress about their sex life.
- Not for everything else. The statement does not support testosterone for energy, mood, bone health, cognition or general wellbeing, and there is not enough data to recommend it for premenopausal women.
- No diagnosis by blood test. A low testosterone result does not diagnose HSDD, and there is no testosterone level that defines female androgen deficiency.
- Female doses only. Transdermal (skin) testosterone is preferred, dosed to approximate the normal premenopausal range. Oral testosterone is not recommended because of its effect on cholesterol, and compounded products are not recommended.
There is no FDA-approved testosterone product for women in the United States. The consensus statement addresses this directly: where no approved female product exists, an approved male product may be used at a small fraction of the male dose, with blood levels checked so they stay within the female physiological range.
The 2026 FDA review of testosterone in menopausal women
Reuters reported in September 2026 that the FDA is reviewing the rising use of testosterone among menopausal women. Prescriptions have grown quickly, much of it through telehealth and wellness marketing that reaches well beyond the single diagnosis the evidence supports.
We will not speculate about what the agency will conclude. What the review signals is already clear from the evidence: testosterone for women works best when it is used for the right reason, at the right dose, with monitoring. If a provider offers testosterone to fix fatigue, weight or mood, or doses it into the male range, that is outside what the Global Consensus supports, whatever the FDA eventually decides.
Non-hormonal FDA-approved options for low desire
Two medications are FDA-approved for acquired, generalized HSDD, and both are approved for premenopausal women only:
- Flibanserin (Addyi): a daily tablet taken at bedtime that acts on brain chemicals involved in desire. Its label carries a warning about alcohol, because the combination can cause low blood pressure and fainting.
- Bremelanotide (Vyleesi): an injection you give yourself under the skin before anticipated sex. It works on melanocortin receptors in the brain. Nausea is a common side effect.
Both produce modest average benefits, and neither is approved for postmenopausal women. They are worth knowing about because they show that low desire is often a brain chemistry question, not only a hormone question. For lifestyle and relationship factors that also shape desire, see our guides on natural ways to boost female libido and what drives libido in men and women.
Safety: female physiological range and ongoing monitoring
Hormones are powerful, which is exactly why dose and follow-up matter. For estrogen, The Menopause Society's 2022 position statement concludes that for healthy women under 60 or within 10 years of menopause, the benefits of hormone therapy for bothersome symptoms generally outweigh the risks, with the decision individualized to your history. Women with a uterus need a progestogen alongside systemic estrogen to protect the uterine lining.
For testosterone, the Global Consensus sets out a clear monitoring approach:
| What gets checked | Why it matters |
|---|---|
| Baseline total testosterone | Establishes your starting point before treatment |
| Repeat level after a few weeks | Confirms you are in the female physiological range, not above it |
| Ongoing levels during treatment | Catches gradual drift upward and possible overuse |
| Signs of androgen excess: acne, unwanted hair growth | Early signals that the dose is too high |
| Response at six months | If there is no benefit, the statement advises stopping |
Long-term safety data for testosterone in women are limited, which is another reason to keep doses physiological and reassess regularly rather than continue by default.
How BioCure evaluates low libido in women
A decade ago, most women were told low desire was just part of getting older. In 2026, the better question is why, and that starts with data. BioCure's Comprehensive Female Panel covers hormones including estrogen and progesterone, plus thyroid, lipids and metabolic markers, as part of a 90+ biomarker panel. You can test with an at-home kit and an in-home phlebotomist visit, or in a lab, with results in 7 to 14 days.
Every result is interpreted with a specialist in a 1:1 review, where your physician looks at the full picture: menopausal stage, symptoms, pain, sleep, thyroid function and medications. Whether hormone therapy is appropriate, and which kind, is decided at that consultation based on your history and results. Learn more about our diagnostics and the physician-led team behind them.
The practical details: the video consultation is $199 and can be credited back with a membership. BioCure is licensed in 47 states, with availability confirmed at intake, and appointments can be in person in the Fort Lauderdale area or by video. BioCure does not bill insurance directly, but many patients use HSA or FSA funds, and we provide documentation for reimbursement.
Frequently asked questions
Does estrogen increase libido in women?
Not directly for most women. Vaginal estrogen treats dryness and painful sex, which often restores interest, and systemic estrogen gives a small to moderate improvement in sexual function mainly in women with menopausal symptoms. A Cochrane review found little or no benefit in postmenopausal women who were not selected for symptoms.
Can women take testosterone for low sex drive?
Yes, but the evidence supports it for one diagnosis: hypoactive sexual desire disorder in postmenopausal women. The 2019 Global Consensus Position Statement recommends transdermal testosterone dosed to the female physiological range, with blood level monitoring. It is not supported for energy, mood or general wellbeing.
Is there an FDA-approved testosterone for women?
No. There is no FDA-approved testosterone product for women in the United States. The Global Consensus allows an approved male product to be used at a small fraction of the male dose, with levels checked to stay in the female range, and it advises against compounded testosterone.
How long does testosterone take to work for libido in women?
Any benefit usually shows up over weeks to a few months. The Global Consensus advises rechecking blood levels after a few weeks and stopping treatment if there is no benefit after six months.
What is the best treatment for painful sex after menopause?
Low dose vaginal estrogen is the standard first prescription option when lubricants and moisturizers are not enough, according to The Menopause Society's 2022 position statement. Prasterone (vaginal DHEA) and oral ospemifene are FDA-approved alternatives for painful sex caused by menopause.
Do I need blood work before hormone therapy for libido?
Blood work does not diagnose low desire, but it helps rule out other causes such as thyroid problems and gives a baseline before any hormone is started. For testosterone, a baseline level is needed so your clinician can keep you in the female physiological range.
Your sex drive is not a luxury; it is part of how you live. The right answer depends on whether the problem is pain, menopausal symptoms or desire itself, and that is a question worth answering with data rather than guesswork.
Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838. Your future self will thank you.